Granules India has informed that the US FDA has completed a GMP inspection of the facility of Granules Pharmaceuticals, Inc., a wholly-owned foreign subsidiary of the Company located in Chantilly, Virginia, USA from 11th December 2023 through 15th December 2023 with five observations. Granules Pharmaceuticals, Inc. will respond to these observations within the stipulated time and does not anticipate any disruptions to its business.
The above information is a part of company’s filings submitted to BSE.
